Ignorer et passer au contenu
Now available in the U.S. - Free Shipping on Your First Order

A prescription-ready bladder support your patients can actually self-manage. 

Cntrl+ is an FDA-cleared, reusable bladder support device for stress urinary incontinence. Non-surgical. Non-hormonal. No in-office fitting required.

Visit us at booth #202

The patient who never brings it up.

1 in 3 women experience SUI. Most won’t raise it unprompted.
Those who do are typically offered pads or a surgical referral.
Neither meets women where they are.

Now give her a real option.

  • Non-surgical, non-hormonal. Expands your conservative toolkit.
  • No in-office fitting required. Patient self-manages at home.
  • Fits into her life, not the other way around.
  • FSA/HSA eligible. Fewer access barriers for your patients.
  • No referral paperwork. No follow-up billing required.

Cntrl+ usability study

University of Ottawa, 2025. Phase 3 prospective home-use. PI: Dr. Linda McLean, PhD. Ethics approval REH H-08-24-10675.

Reported reduced or eliminated bladder leaks (16 of 18 participants*)

Maintained normal voiding while wearing the device (17 of 20 participants)

Reported ease of care over two weeks (19 of 20 participants)

All claims sourced from the McLean Usability and Effectiveness Study (University of Ottawa, November 2025).
2-week home-use study, n=20. Individual patient outcomes may vary.

How Cntrl+ works for your patients

No fitting. No inventory. A simple patient referral process.
We handle intake, prescription review, and delivery. 

Refer your patients in under a minute.

STEP 01

Patient completes a short online intake

She visits cntrlplus.com, answers a brief health questionnaire, and submits. No in-office time required from your practice. 

No appointment needed.

STEP 02

A licensed prescriber reviews and approves

An asynchronous clinical review, within 4 hours. No chair time. 

Ships direct. No inventory required.

*Coming soon: prescribing from your EHR. 

STEP 03

Starter Kit ships directly to your patient

Three sizes for self-fitting at home. One prescription covers the Starter Kit plus 11 refills. 

HSA / FSA eligible.

"I have been managing this for fifteen years. This is the first product that matched what my pessary does, and it is easier to use." 

-Nancy S. · Age 76 · Menlo Park, CA 

Prescribing pathway

Refer your patient to cntrlplus.com. They complete a short online health intake, a licensed provider reviews it, and if approved a prescription is issued - all online, no office visit required.

How it works for the patient

Step 1 Visit cntrlplus.com
Step 2 Complete health intake online
Step 3 Licensed provider reviews & approves
Step 4 Device ships to patient's door

No referral paperwork or provider action required. FSA/HSA eligible - Letter of Medical Necessity provided to patient upon request.

Patient cost

Starter Kit $159
FSA / HSA Eligible
LMN Provided upon request
Refills Single size, on demand

Three Cntrl+ devices demonstrations sizes 'L', 'M', and 'S' on a white background

Coming soon: prescribing from your EHR. 

Cntrl+ is FSA and HSA eligible with a letter of medical necessity. Patient evaluation may be billed via telehealth or an in-office code.  

For more information, and to learn how to prescribe from your EHR, contact partnerships@cntrlplus.com

A Letter of Medical Necessity is provided to the patient upon request. Patients need this to submit FSA or HSA claims. No additional paperwork required from the prescribing provider.

Required documentation:

  • Diagnosis of stress urinary incontinence
  • Clinical rationale for conservative management
  • Physician decision to use bladder support device
  • Statement that device was dispensed under physician direction
  • Date device was furnished

Replace every 90 days.

Between conservative management and surgery.

For patients who prefer non-surgical management - or who are not yet surgical candidates - Cntrl+ fills a clinical gap that absorbent products cannot address.

  • It's not a pad (reactive absorbent, no prevention)
  • It's not surgery (invasive, recovery time, referral delay)
  • It's not a pessary (semi-permanent, clinic-managed)
  • It's not complicated (fits in-office or self-fits at home)
FDA cleared
510(k) K240798
Prescription device
EHR via Honeybee Health
Dx N39.3
FSA / HSA eligible
Zero adverse events
90% leakage reduction
Active during movement

Designed for the patients between pads and surgery.

Cntrl+ was built for the patients most likely to go unaddressed - active women managing SUI who want more flexibility than a pessary can offer.

Indicated for physical activity
Designed for running, lifting, and high-impact movement - effective during the moments absorbent products cannot prevent.
Flexible prescribing pathways
Self-fitted at home with the three-size Starter Kit. Ships via Honeybee Health. No in-office inventory required.
Non-surgical. Non-invasive.
A first-line conservative option for patients who are not yet surgical candidates, or who prefer to avoid intervention while remaining active.

I used Cntrl+ while leading a kids after school fitness program - sprinting, jumping, cutting. I'm usually bracing and can only do a few jumps before needing to rest. Today while using the product I had zero urgency. This thing is awesome!

-Katie R., PT, DPT · Pelvic floor PT · KOL

Clinician-led. Evidence-anchored.

Developed with input from leading researchers and clinicians across urogynecology, pelvic floor medicine, and women's health. Every clinical claim on this page has been reviewed by the Medical Advisory Board.

Dr. Bertha Chen, MD

Chair, Medical Advisory Board
Stanford University. Molecular and regenerative medicine, women's health, telemedicine.

Dr. Mary Polan, MD, PhD

Medical Advisory Board
Yale University. Reproductive endocrinology and women's health research.

Dr. Aisling Clancy

Medical Advisory Board
University of Ottawa. Pelvic floor health, urogynecology, and women's health.

Dr. Linda McLean, PhD

Study Principal Investigator
Full Professor, Women's Health Research, University of Ottawa. PI, McLean Usability Study (2025).

*Rx only. For use under the guidance of a licensed healthcare provider. FDA cleared. Results from a 2-week home-use usability study, n=20. Not a powered clinical efficacy trial. Individual outcomes may vary.*2 neutral responses discounted per approved analytical methodology. Individual patient outcomes may vary